Researchers with the Institute for Memory Impairments and Neurological Disorders (UCI MIND) have discovered how a novel compound can reduce the accumulation of brain plaques seen in Alzheimer's disease without the side effects produced by any current drugs used for the chronic neurodegenerative disease. In a study published online in the Annals of Neurology, neurobiologists Kim Green and Frank LaFerla found that the ST101 compound triggers a process which carves up amyloid precursor proteins into benign molecules. These precursor proteins, when intact, ultimately can form into beta-amyloid plaques, which are the hallmark lesions of Alzheimer's and believed to be the primary cause of dementia caused by the disease. The researchers believe that ST101 has the potential to be used as the basis of a drug therapy for people who have mild Alzheimer's symptoms.
Publication: ST101 induces a novel 17kDa APP cleavage that precludes Aβ generation in vivo
Kim N. Green PhD, Hasan Khashwji BS, Tatiana Estrada MS, Frank M. LaFerla PhDArticle first published online: 17 MAR 2011
Source: University of California Irvine
Bookmark/Search this post with